Department of Medical Microbiology (Schering AG)

Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

Retrieved on: 
Monday, September 11, 2023
Department of Medical Microbiology (Schering AG), Abstract, Pelvic inflammatory disease, Bachelor of Science, University, Apotex, Medical microbiology, HIV, Cangene, HIV-1, Head, Monoclonal antibody, Public Health Agency of Canada, COVID-19, Woman, CIHR, Infection, Research, Lehigh University, American Biological Safety Association, National Microbiology Laboratory, University of Manitoba, Government, Immunochemistry, Chlamydia trachomatis, Philosophy, Outline, Gynaecology, Blood, Scripps Research, Protein engineering, R, Public Health Agency, G.H. Raisoni Department of Microbiology and Biotechnology, University Arena (Western Michigan University), Vaccine, Science, Chlamydia, Molecular biology, Aspira

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
  • Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
  • Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.

Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases

Retrieved on: 
Wednesday, August 24, 2022
University, COVID-19, Medicine, HBV, Safety, Securities Exchange Act of 1934, Program, Securities Act of 1933, Research, Hepatitis B virus, SAN, Doctor of Philosophy, Genital herpes, Nobel Prize in Physiology or Medicine, Hepatitis, Sumathi Best Television Current Reporting Award, Department of Medical Microbiology (Schering AG), Department, Medical microbiology, SEC, U.S. Securities and Exchange Commission, Degenerative disease, Immunology, Assembly, Nobel Prize, GLOBE, Leadership, Therapy, Investor, Annual report, Q&A, Event, Patient, Vaccine, Pharmaceutical industry, Virology, Physiology, Nobel

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, plans to host a research webcast on Wednesday, August 31, 2022, from 1:30-2:30 pm PT/4:30-5:30 pm ET. The event will highlight two new small molecule research programs that expand the company’s portfolio beyond core inhibitors and hepatitis B/delta viruses. The first program targets a differentiated antiviral approach against herpes simplex virus type 2 (HSV-2) for patients with recurrent genital herpes. The second is advancing a pan-herpes antiviral for serious transplant-associated viral infections.

Key Points: 
  • The event will highlight two new small molecule research programs that expand the companys portfolio beyond core inhibitors and hepatitis B/delta viruses.
  • The first program targets a differentiated antiviral approach against herpes simplex virus type 2 (HSV-2) for patients with recurrent genital herpes.
  • Assembly Bio is a clinical-stage biotechnology company pioneering the development of novel therapeutics for serious viral diseases.
  • Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL

Retrieved on: 
Thursday, July 21, 2022
Knowledge, IBD, Bacteria, GLOBE, University Medical Center Utrecht, Department of Medical Microbiology (Schering AG), Research, CEO, NFU, Neurodegeneration, Microbiome, Inflammatory bowel disease, Partnership, Solution, Immunoglobulin A, Associate, Health, University Medical Center, Pass, Medical microbiology, Cancer, Ira Pastan, Inflammation, Journal, Technology, UMC, Patient, Department, Virulence, Therapy, Yale University, ICI, Pharmaceutical industry, HAVEN, M.A, Artizans, Labourers & General Dwellings Company

We look forward to working with UMC Utrecht and Microviable to identify potential solutions that can improve patient outcomes and reduce the side effects of ICI treatment.

Key Points: 
  • We look forward to working with UMC Utrecht and Microviable to identify potential solutions that can improve patient outcomes and reduce the side effects of ICI treatment.
  • Artizan is creating multiple programs validated by strategic alliances that include Biohaven Pharmaceuticals, Brii Biosciences, and Crohns and Colitis Foundation.
  • The University Medical Center of Utrecht (UMC Utrecht) is one of the largest public healthcare institutions in the Netherlands.
  • UMC Utrecht is one of the participating centers in the NFU, which is the Dutch organization for University Medical Centers.

Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine

Retrieved on: 
Monday, February 7, 2022
News, Light, Trial of the century, GLOBE, Forward-looking statement, Department, Daou Technology Inc., Medical microbiology, TSX Venture Exchange, PHAC, CRA, Research, National Microbiology Laboratory, Company, University of Manitoba, Risk, Bacteria, CSS, Technology, PDC, Department of Medical Microbiology (Schering AG), Patient, University, Public Health Agency, TLT, UM, Animal, TSX, Coronavirus, Head, Reactive oxygen species, Oxidative stress, Public Health Agency of Canada, Cancer, Virus, Interim, Influenza, Biological hazard, Cell, COVID-19, Pharmaceutical industry, Vaccine

Under the terms of the agreement, Theralase and PHAC are collaborating on the research, development and optimization of a COVID-19 vaccine by inactivating the SARS-CoV-2 virus with Theralases light-activated PDC, TLD-1433.

Key Points: 
  • Under the terms of the agreement, Theralase and PHAC are collaborating on the research, development and optimization of a COVID-19 vaccine by inactivating the SARS-CoV-2 virus with Theralases light-activated PDC, TLD-1433.
  • These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.
  • The research also demonstrates that the Theralase platform is extremely versatile, with an ability to be applicable to a wide range of enveloped viruses.
  • Based on this encouraging data, the Company intends to move forward in the research, development and commercialization of the Theralase COVID-19 vaccine, subject to the required regulatory approval.